Sugi Predict

Sugi Predict / Compounds / SCHEMBL180861

SCHEMBL180861

SCHEMBL180861

CCOC(=O)CCNC(=O)CC1CCC(c2ccc(-c3cnc(Nc4cccc(Cl)c4)o3)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 7/20 0.49
▸ EGFR P00533 1/20 0.41
▸ SIRT7 Q9NRC8 1/20 0.41
▸ LMNA P02545 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ TP53 P04637 2/20 0.38
▸ MDM2 Q00987 1/20 0.38
▸ VCP P55072 1/20 0.38
▸ FLT1 P17948 3/20 0.38
▸ FLT4 P35916 3/20 0.38
▸ KDR P35968 3/20 0.38
▸ CNR2 P34972 2/20 0.37
▸ HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL180506 0.91 DGAT1 (0.52) DGAT1EGFRSIRT7LMNAMAPT
SCHEMBL180832 0.89 DGAT1 (0.59) DGAT1SIRT7VCPFLT1FLT4
SCHEMBL16549688 0.89 DGAT1 (0.59) DGAT1SIRT7VCPFLT1FLT4
SCHEMBL13664066 0.89 DGAT1 (0.59) DGAT1SIRT7VCPFLT1FLT4
SCHEMBL14617025 0.82 DGAT1 (0.64) DGAT1SIRT7VCPFLT1FLT4
SCHEMBL16546760 0.82 DGAT1 (0.64) DGAT1SIRT7VCPFLT1FLT4
SCHEMBL180807 0.82 DGAT1 (0.64) DGAT1SIRT7VCPFLT1FLT4
SCHEMBL180696 0.82 DGAT1 (0.64) DGAT1SIRT7VCPFLT1FLT4
SCHEMBL27758115 0.80 DGAT1 (0.52) DGAT1SIRT7LMNAMAPTVCP
SCHEMBL13664067 0.79 DGAT1 (0.54) DGAT1SIRT7VCPFLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150065517-A1 NEW COMPOUNDS NOVARTIS AG (CH) 2015-03-05 — — US disclosed
US-8912208-B2 (4-{4-[5-(benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid useful for treating or preventing conditions or disorders associated with DGAT1 activity NOVARTIS AG (CH) 2014-12-16 — — US disclosed
US-8835451-B2 Compounds NOVARTIS AG (CH) 2014-09-16 — — US disclosed
US-20130018074-A1 NEW COMPOUNDS NOVARTIS AG (CH) 2013-01-17 — — US disclosed
US-20130018054-A1 NEW COMPOUNDS NOVARTIS AG (CH) 2013-01-17 — — US disclosed
EP-2418202-A1 New compounds Novartis AG (CH) 2012-02-15 — — EP disclosed
EP-2404905-A1 New compounds Novartis AG (CH) 2012-01-11 — — EP disclosed
EP-2402319-A1 DGAT Inhibitors Novartis AG (CH) 2012-01-04 — — EP disclosed
EP-2402320-A1 Anorectic agents Novartis AG (CH) 2012-01-04 — — EP disclosed
EP-2402318-A1 DGAT inhibitors Novartis AG (CH) 2012-01-04 — — EP disclosed
EP-2402317-A1 DGAT inhibitor Novartis AG (CH) 2012-01-04 — — EP disclosed
EP-2301923-A1 New compounds Novartis AG (CH) 2011-03-30 — — EP disclosed
US-20090247534-A1 NEW COMPOUNDS NOVARTIS AG (CH) 2009-10-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150065517-A1 NEW COMPOUNDS DGAT1, DGAT2, GBA1 DGAT1 1/4885EGFR 4495/4885SIRT7 2995/4885
US-20090247534-A1 NEW COMPOUNDS DGAT1, DGAT2, GBA1 DGAT1 1/4885EGFR 4495/4885SIRT7 2995/4885
US-20130018054-A1 NEW COMPOUNDS DGAT1, DGAT2, GBA1 DGAT1 1/4885EGFR 4483/4885SIRT7 2961/4885
US-20130018074-A1 NEW COMPOUNDS DGAT1, DGAT2, GBA1 DGAT1 1/4885EGFR 4483/4885SIRT7 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.